The delivery of effective therapeutic cancer vaccination.
Dendritic Cell Biology and Therapeutics, ANZAC Research Institute, Sydney, NSW 2139, Australia. derek.hart@sydney.edu.au
Derek
D
Hart
D000135:Acid Phosphatase / Q000008:administration & dosage / Q000276:immunology; D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000637:transplantation; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000008:administration & dosage*; D017326:Clinical Trials, Phase III as Topic; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014020:Tissue Extracts / Q000008:administration & dosage
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D011993:Recombinant Fusion Proteins; D014020:Tissue Extracts; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C511774:sipuleucel-T; D000135:Acid Phosphatase; C416374:PA2024 fusion protein, human